Department of Physiology, University of Pretoria, South Africa.
Cell Prolif. 2011 Dec;44(6):567-81. doi: 10.1111/j.1365-2184.2011.00789.x. Epub 2011 Oct 13.
To investigate anti-proliferative properties of a novel in silico-modelled 17β-oestradiol derivative (C9), in combination with dichloroacetic acid (DCA), on MCF-7 and MCF-12A cells.
xCELLigence system was employed to determine optimal seeding number for cells, and crystal violet assay was used to assess cell number and to determine IC(50) value (24 h) for combination treatment. Light and fluorescent microscopy techniques were used to morphologically detect types of cell death. Flow cytometry was used to analyse cell cycle and apoptosis.
Optimal seeding number for 96-well plates was determined to be 5000-10 000 cells/well for both MCF-7 and MCF-12A cells. IC(50) for MCF-7 cells of the combination treatment after 24 h was 130 nm of C9 in conjunction with 7.5 mm of DCA (P < 0.05). In contrast, the same concentration inhibited cell population growth by only 29.3% for MCF-12As after 24-h treatment (P < 0.05). Morphological studies revealed lower cell density of both types of combination-treated cells. Flow cytometric analyses demonstrated increase in sub-G(1) phase in combination-treated MCF-7 cells.
These results demonstrate that the novel 17β-oestradiol derivative C9, in combination with DCA is a potent anti-proliferation treatment, with properties of selectivity towards tumourigenic cells. Thus, this warrants further studies as a potential combination chemotherapeutic agent for further cancer cell lines.
研究新型计算机模拟 17β-雌二醇衍生物(C9)与二氯乙酸(DCA)联合对 MCF-7 和 MCF-12A 细胞的抗增殖特性。
采用 xCELLigence 系统确定细胞的最佳接种数,结晶紫法检测细胞数并确定联合治疗的 IC50 值(24 h)。使用荧光和明场显微镜技术从形态学上检测细胞死亡的类型。流式细胞术用于分析细胞周期和凋亡。
确定 96 孔板的最佳接种数为 MCF-7 和 MCF-12A 细胞的 5000-10000 个/孔。24 h 时联合治疗 MCF-7 细胞的 IC50 值为 130 nm 的 C9 与 7.5 mm 的 DCA(P<0.05)。相比之下,相同浓度的药物处理 MCF-12As 24 h 后仅抑制细胞群体生长 29.3%(P<0.05)。形态学研究显示两种联合处理细胞的细胞密度均降低。流式细胞术分析显示联合处理 MCF-7 细胞的亚 G1 期增加。
这些结果表明,新型 17β-雌二醇衍生物 C9 与 DCA 联合是一种有效的抗增殖治疗方法,对肿瘤细胞具有选择性。因此,这进一步证明了它作为一种潜在的联合化疗药物用于进一步的癌细胞系的潜力。